COLUMBUS, Ohio, May 4 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the launch of its generic for Mycophenolate Mofetil 250mg Capsules and 500mg Tablets by the U.S. Food and Drug Administration. These products are available in 250mg Capsules Bottles of 100 and 500, 500mg Tablets Bottles of 100 and 500. These products are available for immediate shipment to wholesalers and pharmacies nationwide.
Roxane Laboratories' Mycophenolate Mofetil 250mg Capsules and 500mg Tablets, are AB rated to CellCept(R) (mycophenolate mofetil) capsules and tablets. Annual sales of Mycophenolate Mofetil are approximately $1,017 Million(1).
Full prescribing information for Mycophenolate Mofetil Capsules and Tablets is available on the Roxane Laboratories website at www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.
About Roxane Laboratories, Inc.
Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 80 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled- release tablets; nasal sprays, cytotoxics and CII narcotics.
Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.
About Boehringer Ingelheim
Boehringer Ingelheim Corporation based in Ri
|SOURCE Roxane Laboratories, Inc.|
Copyright©2009 PR Newswire.
All rights reserved